• 1
    Lieber CS, Lasker JM, DeCarli LM, Saeli J, Wojtowicz T. Role of acetone, dietary fat and total energy intake in induction of hepatic microsomal ethanol oxidizing system. J Pharmacol Exp Ther 1988; 247: 791795.
  • 2
    Wrighton SA, Thomas PE, Ryan DE, Levin W. Purification and characterization of ethanol-inducible human hepatic cytochrome P-450HLj. Arch Biochem Biophys 1987; 258: 292297.
  • 3
    Raucy J, Fernandes P, Black M, Yang SL, Koop DR. Identification of a human liver cytochrome P-450 exhibiting catalytic and immunochemical similarities to cytochrome P-450 3a of rabbit liver. Biochem Pharmacol 1987; 36: 29212926.
  • 4
    Louis CA, Wood SG, Kostrubsky V, Sinclair PR, Sinclair JF. Synergistic increases in rat hepatic cytochrome P450s by ethanol and isopentanol. J Pharmacol Exp Ther 1994; 269: 838845.
  • 5
    Roberts BJ, Shoaf SE, Song BJ. Rapid changes in cytochrome P4502E1 (CYP2E1) activity and other P450 isozymes following ethanol withdrawal in rats. Biochem Pharmacol 1995; 49: 16651673.
  • 6
    de W, I, Bouguet J, Beaune PH, Gonzalez FJ, Ketterer B, Barouki R. Effects of ethanol, dexamethasone and RU 486 on expression of cytochromes P450 2B, 2E, 3A and glutathione transferase pi in a rat hepatoma cell line (Fao). Pharmacogenetics 1992; 2: 1218.
  • 7
    Feierman DE, Melinkov Z, Nanji AA. Induction of CYP3A by ethanol in multiple in vitro and in vivo models. Alcohol Clin Exp Res 2003; 27: 981988.
  • 8
    Thummel KE, Lee CA, Kunze KL, Nelson SD, Slattery JT. Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP3A4. Biochem Pharmacol 1993; 45: 15631569.
  • 9
    Hoshino U, Kawasaki H. Urinary 6b -hydroxycortisol excretion in patients with alcoholic liver disease. Res Commun Alcohol Sub Abuse 1995; 16: 116124.
  • 10
    Luceri F, Fattori S, Luceri C, Zorn M, Mannaioni P, Messeri G. Gas chromatography-mass spectrometry measurement of 6beta-OH-cortisol/cortisol ratio in human urine: a specific marker of enzymatic induction. Clin Chem Lab Med 2001; 39: 12341239.
  • 11
    St Haxholdt O, Krintel JJ, Johansson G. Pre-operative alcohol infusion: the need for analgesic supplementation in chronic alcoholics. Anaesthesia 1984; 39: 240245.
  • 12
    Lindholm A, Welsh M, Alton C, Kahan BD. Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability. Clin Pharmacol Ther 1992; 52: 359371.
  • 13
    Lindholm A, Welsh M, Rutzky L, Kahan BD. The adverse impact of high cyclosporine clearance rates on the incidences of acute rejection and graft loss. Transplantation 1993; 55: 985993.
  • 14
    Pollak R, Wong RL, Chang CT. Cyclosporine bioavailability of Neoral and Sandimmune in white and black de novo renal transplant recipients. Neoral Study Group. Ther Drug Monit 1999; 21: 661663.
  • 15
    First MR, Schroeder TJ, Monaco AP, Simpson MA, Curtis JJ, Armenti VT. Cyclosporine bioavailability: dosing implications and impact on clinical outcomes in select transplantation subpopulations. Clin Transplant 1996; 10(1 Pt 1): 5559.
  • 16
    Andrews PA, Sen M, Chang RW. Racial variation in dosage requirements of tacrolimus. Lancet 1996; 348: 1446.
  • 17
    Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation 1998; 65: 515523.
  • 18
    Zimmerman JJ, Kahan BD. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 1997; 37: 405415.
  • 19
    MacPhee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002; 74: 14861489.
  • 20
    Mancinelli LM, Frassetto L, Floren LC, Dressler D, Carrier S, Bekersky I, et al. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 2001; 69: 2431.
  • 21
    Yates CR, Zhang W, Song P, Li S, Gaber AO, Kotb M, et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol 2003; 43: 555564.
  • 22
    Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5′-promoter region polymorphism. Clin Pharmacol Ther 2000; 68: 8291.
  • 23
    Floyd MD, Gervasini G, Masica AL, Mayo G, George AL, Jr., Bhat K, et al. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 2003; 13: 595606.
  • 24
    Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner-Daniels B, et al. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther 2003; 74: 275287.
  • 25
    Wang Z, Hall SD, Maya JF, Li L, Asghar A, Gorski JC. Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol 2003; 55: 7785.
  • 26
    Chalasani N, Gorski JC, Asghar MS, Asghar A, Foresman B, Hall SD, et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. HEPATOLOGY 2003; 37: 544550.
  • 27
    Westlind-Johnsson A, Malembo S, Johansson A, Otter C, Anderson TB, Johansson I, et al. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 2003; 31: 755761.
  • 28
    Haufroid V, Toubeau F, Clippe A, Buysschaert M, Gala JL, Lison D. Real-time quantification of cytochrome P4502E1 mRNA in human peripheral blood lymphocytes by reverse transcription-PCR: method and practical application. Clin Chem 2001; 47: 11261129.
  • 29
    Raucy JL, Schultz ED, Wester MR, Arora S, Johnston DE, Omdahl JL, et al. Human lymphocyte cytochrome P450 2E1, a putative marker for alcohol-mediated changes in hepatic chlorzoxazone activity. Drug Metab Dispos 1997; 25: 14291435.
  • 30
    Persson J. Alcohol and the small intestine. Scand J Gastroenterol 1991; 26: 315.
  • 31
    Persson J, Berg NO, Sjolund K, Stenling R, Magnusson PH. Morphologic changes in the small intestine after chronic alcohol consumption. Scand J Gastroenterol 1990; 25: 173184.
  • 32
    Garcia-Puges AM, Elena M, Bordas JM, Bombi JM, Barragan V, Teres J. [Changes in the small intestine mucosa in chronic alcoholism]. Gastroenterol Hepatol 1995; 18: 309314.
  • 33
    Wolbold R, Klein K, Burk O, Nussler AK, Neuhaus P, Eichelbaum M, et al. Sex is a major determinant of CYP3A4 expression in human liver. HEPATOLOGY 2003; 38: 978988
  • 34
    Raucy J, Carpenter SP. CYP2E1. In: LevyRH, ThummelKE, TragerWF, HanstenPD, EichelbaumM, eds. Metabolic Drug Interactions. Philadelphia: Lippincott Williams & Wilkins, 2000: 95114.